CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 567,978	$ 683,971
Operating expenses
Provision for changes in expected cash flows from financial royalty assets	583,600	118,804
Research and development funding expense	500	500
General and administrative expenses	57,652	85,695
Total operating expenses, net	641,752	204,999
Operating (loss)/income	(73,774)	478,972
Other expense/(income)
Equity in losses/(earnings) of equity method investees	14,149	(34,606)
Interest expense	44,232	46,950
Gains on derivative financial instruments	0	(7,090)
(Gains)/losses on equity securities	(77,730)	10,818
Gains on available for sale debt securities	(46,420)	(32,300)
Interest income	(7,417)	(16,702)
Other non-operating expense, net	3,685	2,813
Total other income, net	(69,501)	(30,117)
Consolidated net (loss)/income before tax	(4,273)	509,089
Income tax expense	0	0
Consolidated net (loss)/income	(4,273)	509,089
Net (loss)/income attributable to non-controlling interests	(9,051)	168,334
Net income attributable to Royalty Pharma plc	$ 4,778	$ 340,755
Earnings per Class A ordinary share:
Basic (in dollars per share)	$ 0.01	$ 0.76
Diluted (in dollars per share)	$ 0.01	$ 0.76
Weighted average Class A ordinary shares outstanding:
Basic (in shares)	448,623	445,612
Diluted (in shares)	597,479	607,251
Financial Royalty Assets
Revenues	$ 541,546	$ 664,687
Other Royalty Income
Revenues	$ 26,432	$ 19,284